Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Top Cited Papers
Open Access
- 23 April 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 510 (7504), 278-282
- https://doi.org/10.1038/nature13229
Abstract
Small-molecule compounds that target the BET domain in proteins such as BRD4 have recently been identified as potential anticancer agents; here, the efficacy of the BRD4-targeting compound JQ1 is demonstrated in castration-resistant prostate cancer driven by deregulated androgen receptor action. Small-molecule compounds that target the BET domain chromatin factors such as BRD4 have recently come to the fore as potential anticancer agents in several cancer types. Arul Chinnaiyan and colleagues now demonstrate efficacy of the BRD4-targeting compound JQ1 in castration-resistant prostate cancer driven by deregulated androgen receptor action. They see inhibition of tumour xenograft growth in vivo in a mouse model through a mechanism that appears to endow JQ1 with greater potency than classical androgen receptor antagonists. Castration can control some prostate cancers by reducing levels of male sex hormone levels but tumours can become resistant. The prognosis for castration-resistant prostate cancers is generally poor. This work identifies the targeting of co-activators or mediators of androgen receptor transcriptional signalling as a possible alternative therapeutic strategy. Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signalling1,2,3. Despite the success of recently approved therapies targeting AR signalling, such as abiraterone4,5,6 and second-generation anti-androgens including MDV3100 (also known as enzalutamide)7,8, durable responses are limited, presumably owing to acquired resistance. Recently, JQ1 and I-BET762 two selective small-molecule inhibitors that target the amino-terminal bromodomains of BRD4, have been shown to exhibit anti-proliferative effects in a range of malignancies9,10,11,12. Here we show that AR-signalling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition. BRD4 physically interacts with the N-terminal domain of AR and can be disrupted by JQ1 (refs 11, 13). Like the direct AR antagonist MDV3100, JQ1 disrupted AR recruitment to target gene loci. By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity. In vivo, BET bromodomain inhibition was more efficacious than direct AR antagonism in CRPC xenograft mouse models. Taken together, these studies provide a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer.Keywords
This publication has 42 references indexed in Scilit:
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4Molecular Cell, 2005
- TaqMan ® -Based Quantification of Invasive Cells in the Chick Embryo Metastasis assayBioTechniques, 2004
- Java Treeview—extensible visualization of microarray dataBioinformatics, 2004